Literature DB >> 22633551

Prognostic indexes for brain metastases: which is the most powerful?

Gustavo Arruda Viani1, Lucas Godói Bernardes da Silva, Eduardo Jose Stefano.   

Abstract

PURPOSE: The purpose of the present study was to compare the prognostic indexes (PIs) of patients with brain metastases (BMs) treated with whole brain radiotherapy (WBRT) using an artificial neural network. This analysis is important, because it evaluates the prognostic power of each PI to guide clinical decision-making and outcomes research. METHODS AND MATERIALS: A retrospective prognostic study was conducted of 412 patients with BMs who underwent WBRT between April 1998 and March 2010. The eligibility criteria for patients included having undergone WBRT or WBRT plus neurosurgery. The data were analyzed using the artificial neural network. The input neural data consisted of all prognostic factors included in the 5 PIs (recursive partitioning analysis, graded prognostic assessment [GPA], basic score for BMs, Rotterdam score, and Germany score). The data set was randomly divided into 300 training and 112 testing examples for survival prediction. All 5 PIs were compared using our database of 412 patients with BMs. The sensibility of the 5 indexes to predict survival according to their input variables was determined statistically using receiver operating characteristic curves. The importance of each variable from each PI was subsequently evaluated.
RESULTS: The overall 1-, 2-, and 3-year survival rate was 22%, 10.2%, and 5.1%, respectively. All classes of PIs were significantly associated with survival (recursive partitioning analysis, P < .0001; GPA, P < .0001; basic score for BMs, P = .002; Rotterdam score, P = .001; and Germany score, P < .0001). Comparing the areas under the curves, the GPA was statistically most sensitive in predicting survival (GPA, 86%; recursive partitioning analysis, 81%; basic score for BMs, 79%; Rotterdam, 73%; and Germany score, 77%; P < .001). Among the variables included in each PI, the performance status and presence of extracranial metastases were the most important factors.
CONCLUSION: A variety of prognostic models describe the survival of patients with BMs to a more or less satisfactory degree. Among the 5 PIs evaluated in the present study, GPA was the most powerful in predicting survival. Additional studies should include emerging biologic prognostic factors to improve the sensibility of these PIs.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22633551     DOI: 10.1016/j.ijrobp.2011.12.082

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Analysis of prognostic factors and comparison of prognostic index scores in patients with brain metastases after whole-brain radiotherapy.

Authors:  Judong Luo; Hong Zhu; Yiting Tang; Honglin Wang; Xifa Zhou; Xujing Lu; Shuyu Zhang; Yunhai Li
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer.

Authors:  Alessandro Inno; Vincenzo Di Noia; Ettore D'Argento; Alessandra Modena; Stefania Gori
Journal:  Transl Lung Cancer Res       Date:  2016-12

3.  Does Graded Prognostic Assessment outperform Recursive Partitioning Analysis in patients with moderate prognosis brain metastases?

Authors:  Neil C Estabrook; Stephen T Lutz; Cynthia S Johnson; Simon S Lo; Mark A Henderson
Journal:  CNS Oncol       Date:  2016-03-17

4.  Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases; poststratified by the graded prognostic assessment (GPA).

Authors:  Paul W Sperduto; Ryan Shanley; Xianghua Luo; David Andrews; Maria Werner-Wasik; Richard Valicenti; Jean-Paul Bahary; Luis Souhami; Minhee Won; Minesh Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-09-26       Impact factor: 7.038

5.  Multi-disciplinary management for patients with oligometastases to the brain: results of a 5 year cohort study.

Authors:  Jillian Maclean; Naomi Fersht; Mausam Singhera; Paul Mulholland; Orla McKee; Neil Kitchen; Susan C Short
Journal:  Radiat Oncol       Date:  2013-06-27       Impact factor: 3.481

Review 6.  The management of brain metastases in non-small cell lung cancer.

Authors:  Scott Owen; Luis Souhami
Journal:  Front Oncol       Date:  2014-09-15       Impact factor: 6.244

7.  Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study.

Authors:  Pierre Chabot; Te-Chun Hsia; Jeong-Seon Ryu; Vera Gorbunova; Cristobal Belda-Iniesta; David Ball; Ebenezer Kio; Minesh Mehta; Katherine Papp; Qin Qin; Jane Qian; Kyle D Holen; Vince Giranda; John H Suh
Journal:  J Neurooncol       Date:  2016-09-21       Impact factor: 4.130

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.